Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029197 | 1.00 | BCHE (0.52) | BCHEACHEBACE1SLC18A3SIGMAR1 | |
| SCHEMBL7240145 | 1.00 | BCHE (0.52) | BCHEACHEBACE1SLC18A3SIGMAR1 | |
| SCHEMBL4029196 | 1.00 | BCHE (0.52) | BCHEACHEBACE1SLC18A3SIGMAR1 | |
| SCHEMBL4030955 | 1.00 | BCHE (0.52) | BCHEACHEBACE1SLC18A3SIGMAR1 | |
| SCHEMBL7239120 | 1.00 | BCHE (0.52) | BCHEACHEBACE1SLC18A3SIGMAR1 | |
| SCHEMBL7468131 | 0.91 | CCR5 (0.58) | BCHEACHEBACE1SIGMAR1CCR5 | |
| SCHEMBL7468128 | 0.91 | CCR5 (0.58) | BCHEACHEBACE1SIGMAR1CCR5 | |
| SCHEMBL7468123 | 0.91 | CCR5 (0.58) | BCHEACHEBACE1SIGMAR1CCR5 | |
| SCHEMBL7248619 | 0.88 | ACHE (0.53) | BCHEACHEBACE1SLC18A3SIGMAR1 | |
| SCHEMBL7248624 | 0.88 | ACHE (0.53) | BCHEACHEBACE1SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986389-B1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040147754-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2004-07-29 | — | — | US | disclosed |
| US-6716985-B2 | ALCOHOLISM, PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-06 | — | — | US | disclosed |
| US-6489347-B1 | NOVEL INTERMEDIATE CARBOXALDEHYDES FOR PHARMACEUTICAL PRODUCTS WITH ANTIDEPRESSANT AND ANTI-PARKINSON PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-03 | — | — | US | disclosed |
| US-20020133011-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133011-A1 | Novel process | HTR1A, HTR4, MAOA | BCHE 1912/4885ACHE 415/4885BACE1 506/4885 |
| US-20040147754-A1 | Novel process | HTR1A, HTR4, HTR2B | BCHE 2370/4885ACHE 394/4885BACE1 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.